Limor Kliker

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel

Yaniv Lustig, Neta S. Zuckerman, Ital Nemet et al. · Eurosurveillance · 2021 · 159 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +15

Genome-wide CRISPR screens identify GATA6 as a proviral host factor for SARS-CoV-2 via modulation of ACE2

Ma’ayan Israeli, Yaara Finkel, Yfat Yahalom-Ronen et al. · Nature Communications · 2022 · 51 citations · Full text

Life Sciences, Infectious Diseases, Genome Editing +13

Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience

Mayan Gilboa, Michal Mandelboim, Victoria Indenbaum et al. · The Journal of Infectious Diseases · 2021 · 42 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC

Gili Regev‐Yochay, Tal Gonen, Mayan Gilboa et al. · medRxiv · 2022 · 42 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 – a double-blind, randomized placebo-controlled trial

Asaf Biber, Geva Harmelin, Dana Lev et al. · International Journal of Infectious Diseases · 2022 · 36 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +15